---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-26-000125"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2026-10-19T20:37:08+00:00"
generated_at: "2026-10-19T20:38:05.598897+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Mineralys Therapeutics adds Kristine Peterson and Lonnel Coats to board, expanding to nine directors

## Summary
- Board appointed Kristine Peterson and Lonnel Coats effective Oct. 19, 2026, increasing board size from seven to nine directors.
- Peterson named Class I director with term expiring at 2027 annual meeting and Audit Committee member; Coats Class II with term expiring at 2028 annual meeting and Compensation Committee member.
- Each received on Oct. 19, 2026 an option for 16,600 shares vesting monthly over three years and an RSU award for 12,400 shares vesting annually over three years.
- Board determined both satisfy Nasdaq independence requirements; no arrangements or Item 404(a) related-party transactions disclosed.

## SEC filing metadata
- accession: 0001933414-26-000125
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2026-10-19T20:37:08+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000125/0001933414-26-000125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000125/mlys-20261016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-26-000125
- JSON: https://secwatch.observer/filing/0001933414-26-000125.json
- Plain text: https://secwatch.observer/filing/0001933414-26-000125.txt

## Key facts
- Executive change
  Kristine Peterson was appointed as Class I Director at Mineralys Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000125/0001933414-26-000125-index.htm
- Executive change
  Lonnel Coats was appointed as Class II Director at Mineralys Therapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: Mr. Coats was appointed as a Class II director, with a term expiring at the Company’s 2028 annual meeting of stockholders, and was also appointed to serve as a member of the Compensation Committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000125/0001933414-26-000125-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.